共查询到20条相似文献,搜索用时 15 毫秒
1.
Manning AP Abelovich D Ghadirian P Lambert JA Frappier D Provencher D Robidoux A Peretz T Narod SA Mes-Masson AM Foulkes WD Wang T Morgan K Fujiwara TM Tonin PN 《Human heredity》2001,52(2):116-120
The BRCA2 8765delAG mutation was previously reported in hereditary breast cancer families of French Canadian and Yemenite Jewish descent. Haplotype analysis, using six microsatellite markers that span BRCA2 and two intragenic polymorphisms, was performed on 8765delAG mutation carriers to determine if there was evidence that the mutations were identical by descent. The alleles of the microsatellite markers most closely flanking BRCA2 (D13S1697 and D13S1701) were found to be identical in state in all the mutation carriers. However, the disease-associated allele of one of the intragenic markers differed between the Yemenite Jews and French Canadian families, indicating that the 8765delAG mutation has independent origins in these two geographically and ethnically distinct populations. 相似文献
2.
Hartge P Struewing JP Wacholder S Brody LC Tucker MA 《American journal of human genetics》1999,64(4):963-970
Three founder mutations in the cancer-associated genes BRCA1 and BRCA2 occur frequently enough among Ashkenazi Jews to warrant consideration of genetic testing outside the setting of high-risk families with multiple cases of breast or ovarian cancer. We estimated the prevalence of these founder mutations in BRCA1 and BRCA2 in the general population of Ashkenazi Jews according to age at testing, personal cancer history, and family cancer history. We compared the results of anonymous genetic testing of blood samples obtained in a survey of >5,000 Jewish participants from the Washington, DC, area with personal and family cancer histories obtained from questionnaires completed by the participants. In all subgroups defined by age and cancer history, fewer mutations were found in this community sample than in clinical series studied to date. For example, 11 (10%) of 109 Jewish women who had been given a diagnosis of breast cancer in their forties carried one of the mutations. The most important predictor of mutation status was a previous diagnosis of breast or ovarian cancer. In men and in women never given a diagnosis of cancer, family history of breast cancer before age 50 years was the strongest predictor. As interest in genetic testing for BRCA1 and BRCA2 in the Jewish community broadens, community-based estimates such as these help guide those seeking and those offering such testing. Even with accurate estimates of the likelihood of carrying a mutation and the likelihood of developing cancer if a mutation is detected, the most vexing clinical problems remain. 相似文献
3.
O. Díez Montserrat Domènech María Carmen Alonso Joan Brunet Judit Sanz Joan Cortés Elisabeth del Río Montserrat Baiget 《Human genetics》1998,103(6):707-708
The 185delAG BRCA1 deletion occurs with a high frequency in Ashkenazi Jews. We detected this mutation in two Spanish Gypsy women (the only Gypsy
participants) in an extensive study of 90 high-risk families and 160 women with early-onset breast cancer. One of these Gypsy
women belonged to a high-risk family and the other had had early-onset breast cancer. The mutation was also detected in 1
out of 25 Gypsy samples unrelated to breast cancer. All the samples with the mutation shared the marker alleles present in
Jewish samples with 185delAG. This is the first report of this mutation in a non-Jewish well-defined ethnic population. According
to these findings the carrier frequency of this mutation in Gypsy individuals could be several times higher than that of the
general population, and this should be taken into consideration in genetic screening for cancer in Gypsy populations.
Received: 2 August 1998 / Accepted: 9 October 1998 相似文献
4.
We describe a heteroduplex analysis for the detection of the 185delAG mutation in the BRCA1 gene. The protein truncation test (PTT) has previously been used to identify many of the mutations
in BRCA1 that result in premature termination of the protein. However, we were not able to detect the 185delAG mutation by PTT and suggest that heteroduplex analysis may complement PTT for analysis of BRCA1 mutations. This simple technique
may be useful for studies on the prevalence and the penetrance of the 185delAG mutation.
Received: 16 January 1996 相似文献
5.
6.
7.
8.
9.
10.
11.
A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. 总被引:7,自引:2,他引:5 下载免费PDF全文
V Meiner D Landsberger N Berkman A Reshef P Segal H C Seftel D R van der Westhuyzen M S Jeenah G A Coetzee E Leitersdorf 《American journal of human genetics》1991,49(2):443-449
Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by mutations in the low-density-lipoprotein (LDL) receptor. Here we characterize an LDL-receptor founder mutation that is associated with a distinct LDL-receptor haplotype and is responsible for FH in 35% of 71 Jewish-Ashkenazi FH families in Israel. Sixty four percent (16/25) of the Ashkenazi patients who carry this mutant allele were of Lithuanian origin. The mutation was not found in 47 non-Ashkenazi FH families. This mutation was prevalent (8/10 FH cases) in the Jewish community in South Africa, which originated mainly from Lithuania. The mutation, a 3-bp in-frame deletion that would result in the elimination of Gly197, has been previously designated FH-Piscataway. PCR amplification of a DNA fragment that includes the mutation in heterozygous individuals results in the formation of a heteroduplex that can be demonstrated by PAGE and used for molecular diagnosis. 相似文献
12.
13.
14.
15.
Bansal A Critchfield GC Frank TS Reid JE Thomas A Deffenbaugh AM Neuhausen SL 《Genetic testing》2000,4(1):45-48
Genetic testing for mutations in BRCA1 and BRCA2, two genes predisposing to breast and ovarian cancers, is available to women with a relevant family history. The aim of this study was to estimate the positive and negative predictive value of clinical sequence analysis of these genes. A reference graph showing positive and negative predictive values over a range of pre-test risk was derived, taking into account the sensitivity and specificity of a full-sequence analysis test. High positive and negative predictive values were found for women with pre-test risk between 4% and 40%, a range of risk commonly seen in clinical testing. The predictive value of full sequence and single-site analysis of BRCA1 and BRCA2, therefore, compares favorably with other diagnostic medical tests. Our results provide a numerical estimate of the predictive value of BRCA testing, and as such, provide a valuable tool to healthcare providers and families as they interpret BRCA1 and BRCA2 test results. 相似文献
16.
McGee J Kotsopoulos J Lubinski J Lynch HT Rosen B Tung N Kim-Sing C Karlan B Foulkes WD Ainsworth P Ghadirian P Senter L Eisen A Sun P Narod SA;Hereditary Breast Cancer Clinical Study Group 《Obesity (Silver Spring, Md.)》2012,20(6):1288-1292
Studies conducted among women in the general population suggest that various anthropometric measures, including height and weight, may be associated with the risk of developing ovarian cancer. Whether such an association exists among women who carry a BRCA1 or BRCA2 mutation has not been evaluated. Thus, we investigated the association between height, weight, changes in body weight, and BMI, and the risk of developing ovarian cancer among 938 women carrying a BRCA1 or BRCA2 mutation. A matched case-control study was conducted in 469 pairs of women carrying a deleterious mutation in either BRCA1 (n = 403 pairs) or BRCA2 (n = 66 pairs). Information about height and weight at ages 18, 30, and 40 was collected from a questionnaire routinely administered to women during the course of genetic counseling. Conditional logistic regression was used to estimate the association between these body size measures and the risk of ovarian cancer. Height, weight, and BMI were not associated with the risk of ovarian cancer (P-trend ≥ 0.15). Also, there was no association between changes in body weight between ages 18-30, or ages 30-40, or ages 18-40 and the risk of ovarian cancer (P-trend ≥ 0.28). The results from this study suggest that height, weight, or weight gain do not influence the risk of ovarian cancer among carriers of a BRCA1 or BRCA2 mutation. 相似文献
17.
BRCA1 mutations have long been associated with altered apoptosis. We have recently reported that caspase 3 activation is increased in human ovarian surface epithelial (OSE) cells expressing a germline N-terminal BRCA1 185delAG mutation. Here, we report increased caspase 3 activity in 185delAG OSE cells associated with decreased expression of cIAP-1 and X-linked inhibitor of apoptosis (XIAP), and decreased ubiquitination of caspase 3. Overexpression of XIAP restored active caspase 3 ubiquitination and lowered levels of caspase 3 activity. Further, the BRCA1 185delAG mutation was associated with reduced levels of phosphorylated Akt1. Transfection with activated Akt1 led to increased cIAP-1 and XIAP levels similar to that seen in BRCA1 185delAG cell lines. Taken together, these data suggest a direct link between the BRCA1 185delAG mutation and alterations in the caspase-mediated apoptotic pathway. 相似文献
18.
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. 总被引:12,自引:10,他引:2 下载免费PDF全文
L S Friedman C I Szabo E A Ostermeyer P Dowd L Butler T Park M K Lee E L Goode S E Rowell M C King 《American journal of human genetics》1995,57(6):1284-1297
19.
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. 总被引:14,自引:1,他引:13 下载免费PDF全文
D Abeliovich L Kaduri I Lerer N Weinberg G Amir M Sagi J Zlotogora N Heching T Peretz 《American journal of human genetics》1997,60(3):505-514
The mutations 185delAG, 188del11, and 5382insC in the BRCA1 gene and 6174delT in the BRCA2 gene were analyzed in 199 Ashkenazi and 44 non-Ashkenazi Jewish unrelated patients with breast and/or ovarian cancer. Of the Jewish Ashkenazi women with ovarian cancer, 62% (13/21) had one of the target mutations, as did 30% (13/43) of women with breast cancer alone diagnosed before the age 40 years and 10% (15/141) of those with breast cancer diagnosed after the age 40 years. Age at ovarian cancer diagnosis was not associated with carrier status. Of 99 Ashkenazi patients with no family history of breast and/or ovarian cancer, 10% carried one of the mutations; in two of them the mutation was proved to be paternally transmitted. One non-Ashkenazi Jewish ovarian cancer patient from Iraq carried the 185delAG mutation. Individual mutation frequencies among breast cancer Ashkenazi patients were 6.7% for 185delAG, 2.2% for 5382insC, and 4.5% for 6174delT, among ovarian cancer patients; 185delAG and 6174delT were about equally common (33% and 29%, respectively), but no ovarian cancer patient carried the 5382insC. More mutations responsible for inherited breast and ovarian cancer probably remain to be found in this population, since 79% of high-incidence breast cancer families and 35% of high-incidence breast/ovarian cancer families had none of the three known founder mutations. 相似文献